GUB-UCN2 / Gubra - LARVOL DELTA

A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D (clinicaltrials.gov) - P1/2 | N=188 | Recruiting | Sponsor: Gubra A/S | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D (clinicaltrials.gov) - P1/2 | N=188 | Not yet recruiting | Sponsor: Gubra A/S

First-in-human • New P1/2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats (ADA 2026) - "GUB-UCN2 monotherapy increased lean and muscle mass while reducing fat mass in aged DIO rats. In combination with semaglutide, GUB-UCN2 preserved and expanded lean and muscle mass during weight loss, further enhanced fat mass reduction, and improved glycemic control and lipid profiles. These results support GUB-UCN2 as a promising therapeutic candidate to preserve and expand muscle mass and enhance fat loss, alone or in combination with GLP-1 receptor agonist therapies."

Combination therapy • Monotherapy • Preclinical • Metabolic Disorders • Obesity • LEP

A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D (clinicaltrialsregister.eu) - P1 | N=220 | Not yet recruiting | Sponsor: Gubra A/S

First-in-human • New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus